Squawk on the Street Shutdown Deal Rally, AI Trade After a Rough Week, Pfizer CEO on Metsera Deal 11/10/25
Nov 10, 2025
Albert Bourla, Chairman and CEO of Pfizer, joins the discussion to share insights on Pfizer's strategic acquisition of Metsera for up to $10 billion, targeting the obesity drug market. He emphasizes the company's robust development capabilities and outlines the potential for product differentiation in obesity therapies. Bourla tackles regulatory implications and competitive dynamics with major players like Novo Nordisk. The hosts also explore market reactions to a potential government shutdown deal and the challenges facing the tech sector amid AI valuation concerns.
AI Snips
Chapters
Transcript
Episode notes
Tentative Shutdown Deal Eases Economic Strain
- The Senate cleared a procedural 60-40 vote that could end the long government shutdown and restore SNAP, veterans, and agriculture funding.
- The deal funds part of the government through next September and continues the rest until January 30, reversing federal employee firings and promising a vote on health care tax credits.
AI Headlines Drive Short-Term Tech Volatility
- Tech and AI stocks rebounded after a rough week, driven by headlines around OpenAI revenue and leadership remarks.
- Market skepticism about AI valuations persists and will factor into upcoming earnings and investor sentiment.
Remain Disciplined Around AI Hype
- Stay invested in leading AI-related names while monitoring earnings and fundamentals ahead of reports.
- Measure enterprise ROI on AI investments rather than chasing headline-driven valuation spikes.